Retatrutide: what the trials show and where it stands with FDA

Retatrutide is the next drug in the line that runs from semaglutide to tirzepatide. Each one acts on one more gut-hormone receptor than the last. The receptor targets describe different molecules rather than a simple ladder of potency. As a marketed treatment, right now, retatrutide isn't approved, can't be prescribed as a marketed drug, and can't be legally compounded.

Retatrutide is a triple-hormone drug still in trials

Retatrutide activates three receptors at once: GIP, GLP-1 and glucagon. The trial papers call it a “triple hormone receptor agonist” ^[5]. Semaglutide acts on GLP-1 alone. Tirzepatide adds GIP. Retatrutide adds glucagon on top.

The trials test one combined triple-receptor molecule. They do not randomize people to separate receptor components, so the observed weight and glucose changes cannot be allocated to one receptor’s contribution. Receptor count alone does not establish greater clinical benefit or a better safety profile than another medicine ^{[5] [7]}.

The four published trials summarized here used once-weekly injections. Because there's no FDA label, there's no approved dose or indication, and no FDA-approved prescribing information establishing the benefit-risk conditions for marketed use. The doses you'll see below are trial arms, not recommendations.

Retatrutide has no approved use; it's being tested for obesity and related conditions

What is retatrutide used for? Nothing yet, officially. It has no approved use. Lilly is testing it for obesity, type 2 diabetes, knee osteoarthritis pain and obstructive sleep apnea. TRIUMPH-1 included a subgroup of 574 people with knee osteoarthritis and 243 with sleep apnea, and found improvements in both ^[5].

Weight, pain and sleep-apnea outcomes do not by themselves establish fewer heart attacks or longer survival. The current TRIUMPH-Outcomes registry lists a cardiovascular and kidney outcomes study as active, not recruiting, with no results posted and estimated primary completion in 2029. That is a study plan and current registry status, not evidence of a benefit or a guaranteed reporting date ^[1].

Phase 3 trials showed up to 25% average weight loss at 80 weeks

In TRIUMPH-1, 2,339 adults with obesity and no diabetes took weekly retatrutide or placebo for 80 weeks. Weight fell 17.6%, 23.7% and 25.0% on the 4, 9 and 12 mg arms, against 3.9% on placebo ^[5].

TRIUMPH-2 reported up to 18.8% average weight loss in participants with type 2 diabetes. Comparing that figure with TRIUMPH-1 does not isolate the effect of diabetes because these are separate trial populations ^[6]. In TRANSCEND-T2D-1, retatrutide on its own lowered A1C by up to 1.94 points in people whose diabetes wasn't controlled by diet and exercise ^[7].

In the knee osteoarthritis subgroup of TRIUMPH-1, pain scores improved by 3.4 to 4.1 points on retatrutide against 2.5 on placebo, on a scale from 1 to 10 ^[5]. These are intention-to-treat changes. In the sleep apnea subgroup, apnea/hypopnea events fell by 32.1 to 34.3 events an hour on the two higher arms, against 9.6 on placebo.

Side effects so far are mostly stomach-related, with a heart-rate signal

Gastrointestinal events were the most common adverse events in the cited trials. Dose relationships differed by symptom and study. In the phase 2 trial they were mostly mild to moderate, and heart rate rose in a dose-dependent way, peaking at 24 weeks and then declining ^[8]. In TRANSCEND-T2D-1, 2% to 5% of people on retatrutide stopped because of side effects, against none on placebo, and no severe low blood sugar was reported ^[7].

That's an incomplete picture by design. Trials are built to find benefits and common harms. The cited trials cannot rule out rare harms, describe every long-term interaction or establish safety in excluded populations. Any future approval would include a reviewed label, but a label also does not enumerate every possible adverse effect. Retatrutide doesn't have one yet.

FDA hasn't approved retatrutide, and it can't legally be compounded

Right now, retatrutide isn't approved for any use and isn't on FDA's list of 2026 novel drug approvals ^[3]. FDA states plainly that “retatrutide and cagrilintide cannot be used in compounding under federal law” ^[2]. Semaglutide and tirzepatide are ingredients of approved drugs, but that fact alone does not authorize every compounded preparation. Their 503A/503B and essentially-copy conditions still need to be satisfied.

Can you get retatrutide outside a trial? An authorized trial is one regulated investigational pathway. Lilly also lists a single-patient expanded access program, which a treating physician has to request. It's limited to adults with severe obesity (a BMI of 35 or more plus at least two serious or life-threatening complications) despite adherence to and tolerance of the highest available chronic weight-management therapy, who cannot join a retatrutide or comparable trial and have discussed standard options including surgery ^[4]. For the legal side in detail, read whether retatrutide can be obtained legally.

A consumer-marketed vial does not establish the trial supply or safeguards

An ordinary online retail offer does not establish an authorized investigational medicine or the same controlled supply chain and oversight as a Lilly trial. FDA has warned companies that illegally sold unapproved drugs containing retatrutide and similar compounds “falsely labeled ‘for research purposes’ or ‘not for human consumption,’” and says these products were sold to consumers for human use with dosing instructions ^[2]. FDA urges people not to buy them, because they're “of unknown quality and may be harmful.”

FDA's broader warning applies too. Illegally marketed GLP-1 products may be counterfeit, may contain the wrong or harmful ingredients, or may contain too little, too much or none of the active ingredient ^[2]. A “research use only” label doesn't make a product legal for people. A seller’s testing claim cannot establish an approved treatment or guarantee the contents, sterility and appropriate use of every vial.

If you're interested in retatrutide, start with your doctor and the public trial listings

The legitimate paths are narrow but real. Trials are listed publicly on ClinicalTrials.gov, where Lilly registers its retatrutide studies along with their enrollment status and sites. A doctor can help you judge whether one fits and can ask about expanded access if you meet its strict criteria ^[4].

• Ask whether an approved drug, such as semaglutide or tirzepatide, fits your goals now.
• Ask whether you might qualify for a retatrutide trial, and what being in one involves.
• If your doctor thinks you meet the expanded-access criteria, ask them to contact the sponsor; patients can't request it themselves.
• Don't buy anything sold as retatrutide online.

Waiting is a reasonable choice too. If FDA approves retatrutide, the label will set out who it's for, the approved doses and reviewed warnings and precautions for marketed use. Neither a future label nor current trial reports can rule out every possible risk.

Retatrutide is a different molecule from Ozempic and Zepbound

Is retatrutide the same as Ozempic? No. Ozempic is semaglutide, an approved drug that acts on one receptor, GLP-1. Retatrutide is a different, unapproved molecule that acts on three. It isn't a stronger version of Ozempic, and the two can't be swapped. Zepbound and Mounjaro contain tirzepatide, which acts on two receptors, GIP and GLP-1.

If you want a GLP-1 drug now, the approved options are on our semaglutide and tirzepatide pages. Our retatrutide vs tirzepatide comparison sets the trial results side by side, with the caveats that come with comparing separate trials. For context on what pharmacies can and can't make, see whether compounded tirzepatide is still available and the compounded tirzepatide page, which concerns an ingredient of approved drugs. That does not make a compounded preparation FDA-approved.